Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab vs pemetrexed + platinum in unresectable malignant pleural mesothelioma
CTR20170913Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in pleural mesothelioma, sponsored by Bristol Myers Squibb. Started Sep 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on CTR20170913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170913.